RxDoctor Payments DataLook up a doctor →

Jay Dave, DO

Neurology · Milford, DENPI 1215159488

Payments from drug & device makers

$161,059in general payments, 2019–2025

Across 1,055 payments — averaging $152.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$60K
  • AbbVie$32K
  • Biohaven Pharmaceuticals, Inc.$21K
  • TG Therapeutics, Inc.$13K
  • Sanofi$9K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • plus $18K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen114$59,591
AbbVie(2 entities)216$32,238
Biohaven Pharmaceuticals, Inc.37$21,359
TG Therapeutics, Inc.12$13,232
Sanofi21$8,976
Biohaven Pharmaceutical Holding Company Ltd.25$7,223
Acorda Therapeutics, Inc14$5,160
Novartis74$1,513
EMD Serono, Inc.40$1,085
Amgen(2 entities)36$855
Bristol Myers Squibb32$801
Teva Pharmaceuticals USA, Inc.41$760
Eisai Inc.32$658
Lundbeck LLC25$628
Lilly USA, LLC24$523
Pfizer57$521
Genentech USA, Inc.24$513
E.r. Squibb & Sons, L.L.C.4$493
Jazz Pharmaceuticals Inc.21$469
Amneal Pharmaceuticals LLC18$360
Acadia Pharmaceuticals Inc19$321
AstraZeneca14$292
UCB, Inc.11$272
Sunovion Pharmaceuticals Inc.12$259
Harmony Biosciences LLC4$186
Supernus Pharmaceuticals, Inc.12$185
Merz Pharmaceuticals, LLC6$176
Ipsen Biopharmaceuticals, Inc7$155
Avanir Pharmaceuticals, Inc.9$155
Argenx US, Inc.5$141
Johnson & Johnson(2 entities)6$136
Neurelis, Inc.8$133
Tanabe Pharma America, Inc.6$127
Mallinckrodt Hospital Products Inc.4$126
CSL Behring3$120
Otsuka America Pharmaceutical, Inc.7$120
Adamas Pharmaceuticals, Inc.7$117
Grifols USA, LLC4$85
Livanova USA, Inc.4$76
Abbott3$69
Kyowa Kirin, Inc.4$63
Scilex Pharmaceuticals Inc.3$62
Sumitomo Pharma America, Inc.3$59
Revance Therapeutics, Inc.1$59
Catalyst Pharmaceuticals, Inc.2$53
Boston Scientific2$51
Vanda Pharmaceuticals Inc.2$51
Life Molecular Imaging Ltd1$48
Insightec,inc2$45
GE HealthCare2$44
Takeda Pharmaceuticals U.S.A., Inc.1$38
ANI Pharmaceuticals, Inc.1$33
Merz North America, Inc.2$33
SK Life Science, Inc.2$30
Mallinckrodt Enterprises LLC1$27
Averitas Pharma Inc.1$26
Resmed Corp1$23
Alnylam Pharmaceuticals Inc.1$23
Medtronic1$21
Cycle Pharmaceuticals Inc1$20

How this compares

$161,059 in reported general payments places this provider in the 95th percentile of 61 neurology providers in Delaware.

See all neurology providers in Delaware →

Medicare billing

Part B allowed, 2024
$480,549
Medicare patients
1,232
Services billed
29,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Milford

See the full list for Delaware →

Where these figures come from

Is this you, or does something look wrong? →